AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease

Stock Information for AN2 Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AN2 Therapeutics Inc.

AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
AN2 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business and Scientific Highlights
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
AN2 Therapeutics to Participate at Upcoming Investor Conferences
AN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.